General Information:

Id: 6,509 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
article
Reference: Bandyopadhyay GK et al.(2006) Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects Diabetes 55: 2277-2285 [PMID: 16873691]

Interaction Information:

Comment In the insulin-resistant groups, the combined activities of AMPK-alpha1 and -alpha2 in the preclamp state were reduced compared with lean control subjects. When the level of phospho-AMPK was normalized to total AMPK protein levels, a similar trend was observed, but the decrease in phosphorylation of AMPK in the insulin-resistant groups was not statistically significant. After 3 months of rosiglitazone treatment in the type 2 diabetic patients, basal levels of AMPK activities were completely normalized, and the inhibitory effect of insulin on AMP kinase activity was largely restored.
Formal Description
Interaction-ID: 61848

drug/chemical compound

Rosiglitazone

affects_activity of

complex/PPI

AMPK

in muscle
Drugbank entries Show/Hide entries for Rosiglitazone